Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

Robert I. Haddad; Christian Nasr; Lindsay Bischoff; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan Yang Duh; Hormoz Ehya; Whitney Goldner; Megan Haymart; Carl Hoh; Jason P. Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M. Lamonica; Bryan McIver; Christopher D. Raeburn; John A. Ridge; Matthew D. Ringel; Randall P. Scheri; Jatin P. Shah; Rebecca Sippel; Robert C. Smallridge; Cord Sturgeon; Thomas N. Wang; Lori J. Wirth; Richard J. Wong; Alyse Johnson-Chilla; Karin G. Hoffmann; Lisa A. Gurski

doi:10.6004/jnccn.2018.0089

Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

Robert I. Haddad, Christian Nasr, Lindsay Bischoff, Naifa Lamki Busaidy, David Byrd, Glenda Callender, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Whitney Goldner, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, Bryan McIver, Christopher D. Raeburn, John A. RidgeMatthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, Karin G. Hoffmann, Lisa A. Gurski

Pathology

Research output: Contribution to journal › Article › peer-review

274 Scopus citations

Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

Original language	English
Pages (from-to)	1429-1440
Number of pages	12
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	16
Issue number	12
DOIs	https://doi.org/10.6004/jnccn.2018.0089
State	Published - Dec 1 2018

Keywords

Antineoplastic Combined Chemotherapy Protocols/standards
Biomarkers, Tumor/analysis
Carcinoma/diagnosis
Clinical Trials as Topic
Humans
Image-Guided Biopsy/methods
Medical Oncology/standards
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors/standards
Proto-Oncogene Proteins B-raf/antagonists & inhibitors
Societies, Medical/standards
Thyroid Gland/diagnostic imaging
Thyroid Neoplasms/diagnosis
Thyroidectomy/methods
Treatment Outcome
United States

Access to Document

10.6004/jnccn.2018.0089

Cite this

Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q. Y., Ehya, H., Goldner, W., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., McIver, B., Raeburn, C. D., ... Gurski, L. A. (2018). Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 16(12), 1429-1440. https://doi.org/10.6004/jnccn.2018.0089

@article{2627e38d5fe743be9aacf36d59265c47,

title = "Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, H{\"u}rthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/standards, Biomarkers, Tumor/analysis, Carcinoma/diagnosis, Clinical Trials as Topic, Humans, Image-Guided Biopsy/methods, Medical Oncology/standards, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors/standards, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Societies, Medical/standards, Thyroid Gland/diagnostic imaging, Thyroid Neoplasms/diagnosis, Thyroidectomy/methods, Treatment Outcome, United States",

author = "Haddad, {Robert I.} and Christian Nasr and Lindsay Bischoff and Busaidy, {Naifa Lamki} and David Byrd and Glenda Callender and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Whitney Goldner and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Peter Kopp and Lamonica, {Dominick M.} and Bryan McIver and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Rebecca Sippel and Smallridge, {Robert C.} and Cord Sturgeon and Wang, {Thomas N.} and Wirth, {Lori J.} and Wong, {Richard J.} and Alyse Johnson-Chilla and Hoffmann, {Karin G.} and Gurski, {Lisa A.}",

year = "2018",

month = dec,

day = "1",

doi = "10.6004/jnccn.2018.0089",

language = "English",

volume = "16",

pages = "1429--1440",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "12",

}

Haddad, RI, Nasr, C, Bischoff, L, Busaidy, NL, Byrd, D, Callender, G, Dickson, P, Duh, QY, Ehya, H, Goldner, W, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, P, Lamonica, DM, McIver, B, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Sippel, R, Smallridge, RC, Sturgeon, C, Wang, TN, Wirth, LJ, Wong, RJ, Johnson-Chilla, A, Hoffmann, KG & Gurski, LA 2018, 'Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 16, no. 12, pp. 1429-1440. https://doi.org/10.6004/jnccn.2018.0089

TY - JOUR

T1 - Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

AU - Haddad, Robert I.

AU - Nasr, Christian

AU - Bischoff, Lindsay

AU - Busaidy, Naifa Lamki

AU - Byrd, David

AU - Callender, Glenda

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Goldner, Whitney

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter

AU - Lamonica, Dominick M.

AU - McIver, Bryan

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sippel, Rebecca

AU - Smallridge, Robert C.

AU - Sturgeon, Cord

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Wong, Richard J.

AU - Johnson-Chilla, Alyse

AU - Hoffmann, Karin G.

AU - Gurski, Lisa A.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

AB - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.

KW - Antineoplastic Combined Chemotherapy Protocols/standards

KW - Biomarkers, Tumor/analysis

KW - Carcinoma/diagnosis

KW - Clinical Trials as Topic

KW - Humans

KW - Image-Guided Biopsy/methods

KW - Medical Oncology/standards

KW - Neoplasm Staging

KW - Prognosis

KW - Protein Kinase Inhibitors/standards

KW - Proto-Oncogene Proteins B-raf/antagonists & inhibitors

KW - Societies, Medical/standards

KW - Thyroid Gland/diagnostic imaging

KW - Thyroid Neoplasms/diagnosis

KW - Thyroidectomy/methods

KW - Treatment Outcome

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85058746008&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000453034100006&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2018.0089

DO - 10.6004/jnccn.2018.0089

M3 - Article

C2 - 30545990

SN - 1540-1405

VL - 16

SP - 1429

EP - 1440

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 12

ER -

Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this